The Danish pharmaceutical giant is quietly advancing a fresh weapon in the obesity wars. Novo Nordisk has registered a first-in-human Phase I trial for an undisclosed weight-loss candidate, NNC0721-8060, which will be tested against its own blockbuster semaglutide — the active ingredient behind Wegovy and Ozempic — across 142 participants. The move signals that management is refusing to rest on its established GLP-1 franchise, even as recent setbacks force a strategic reshuffle of its pipeline.
That recalibration has been anything but smooth. Roughly two weeks ago, the company disclosed disappointing Phase III results from its ZEUS study of Ziltivekimab, which failed to hit its primary endpoint of reducing major cardiovascular events. On top of that clinical miss, Novo Nordisk took a non-cash impairment charge on intangible pipeline assets, including a substantial write-down tied to its obesity candidate Monlunabant. The new NNC0721-8060 study suggests the company is channeling resources into the next wave of anti-obesity therapies rather than doubling down solely on its semaglutide cash cows.
While Novo Nordisk races to protect its market lead, workplace leaders face their own compliance pressures — and the stakes are just as real when it comes to employee safety. A free toolkit with 41 ready-to-use templates and checklists helps you document risks properly and stay ahead of regulatory expectations. Download the free Risk Assessment Toolkit
Competitive Pressure Intensifies on Two Fronts
The timing of the trial registration is hardly coincidental. Across the Atlantic, Eli Lilly has been flexing serious commercial muscle, posting a 48 percent revenue surge to $23 billion in its half-year results, powered by Mounjaro and Zepbound, while lifting its full-year guidance to between $85 billion and $87 billion. Lilly has also signaled encouraging progress on its next-generation obesity candidate, Retatrutide, and recently inked a licensing deal with OmniAb focused on ion-channel drug discovery.
Novo Nordisk now finds itself squeezed from both directions — Lilly’s dominance in the current commercial landscape and its momentum in early-stage research. The competitive dynamics extend beyond pharma rivals, too. Nestlé has announced plans to leverage artificial intelligence in developing nutritional supplements tailored specifically for users of GLP-1 medications from both Novo Nordisk and Eli Lilly, aiming to counteract side effects such as muscle loss. It’s a telling sign of how a full-fledged ecosystem of complementary products is emerging around the weight-loss injection market.
Legal Wins and Capital Returns
On the legal front, Novo Nordisk has scored a notable victory in Europe. A court in The Hague issued a preliminary injunction against Ceban Ziekenhuisfarmacie, barring the pharmacy from manufacturing Semanova, a semaglutide-containing nasal spray, on patent infringement grounds. The ruling requires the pharmacy to halt infringing activities, remove product listings, and disclose supply chain information. The company has also had a quieter month on the litigation front in the US, where a federal judge dismissed an antitrust lawsuit filed by a compounding manufacturer that had accused both Novo Nordisk and Eli Lilly of blocking access to customized GLP-1 preparations.
Meanwhile, the company continues returning capital to shareholders. An interim dividend of 3.75 Danish kroner per Class A and B share was paid out to investors on the register as of August 17, and the ongoing share buyback program — which was expanded just over three weeks ago — remains in motion. Management has also been vocal about its strategic direction: CEO Mike Doustdar told Reuters last Thursday that investors are underestimating demand for differentiated obesity treatments, arguing that new options like oral tablets will prevent the market from becoming a winner-take-all duel with Lilly. He reiterated plans to launch the combination therapy CagriSema next year, despite trial data showing weight-loss results trailing Lilly’s Zepbound. Earlier this month, Doustdar told the Wall Street Journal he remains open to smaller acquisitions but rules out transformative mergers — a clear preference for organic growth over blockbuster dealmaking.
Stock Remains Under Pressure Despite Operational Progress
The half-year results, delivered roughly two weeks ago, provided some fundamental support: adjusted operating profit came in at 33,389 million Danish kroner, and the company raised its full-year guidance for both adjusted sales growth and operating profit. The stock initially responded with a 1.1 percent gain, only to give back ground when the disappointing trial data emerged about two weeks later, knocking the shares down 2.7 percent
The chart tells a story of persistent weakness. The shares were trading around 39.77 euros on Tuesday, up 2.4 percent on the day, but remain far from the 52-week high of 54.86 euros reached in January. Over the past month, the stock has shed 11 percent, and the gap to that January peak now stands at roughly 29 percent. Technical indicators paint a similarly cautious picture: with a relative strength index of 38.5, the stock is technically oversold, yet it continues to trade below both its 50-day moving average of 41.44 euros and its 200-day average of 40.26 euros.
Just as investors scrutinize Novo Nordisk’s pipeline for signs of resilience, UK employers face their own version of due diligence — ensuring every safety document is current and compliant. Over 37,000 British businesses already rely on this free toolkit to protect their teams and stay on the right side of regulations. Get the free Health & Safety Toolkit
The expanded buyback has done little to arrest the decline — the shares have lost 14.1 percent since that announcement three weeks ago, though they have recovered 3.6 percent from the post-earnings trough. Investors appear to be waiting for tangible evidence that Doustdar’s confidence in obesity-drug demand translates into actual sales figures. The new trial registration offers a fresh reason to believe the company’s innovation leadership in the category remains intact — but the market, for now, seems to want proof in the numbers, not just in the pipeline.
Disclaimer…
en | DK0062498333 | NOVO | boerse | 69965411 |
